Pharmaron | Pharmaron API Commercial Synthesis Shaoxing (China)

The Shaoxing site, established in 2022 in China, received NMDA approval for commercial manufacturing in the same year and successfully completed a Pre-Approval Inspection (PAI) by the FDA in 2025.

Backed by a team of 3,500 process chemists, the site supports manufacturing activities from clinical to commercial scale for small molecules (APIs and advanced intermediates) as well as commercial peptides, utilizing reactors ranging from 5L to 12,500L.

A key strength of the site lies in its technological capabilities, including:

• Flow chemistry scaled to commercial production,
• High-potency chemistry (OEB-5) at commercial scale,
• Dedicated biocatalysis and chemical catalysis groups.

The site also houses a material sciences division capable of performing micronization, jet milling, wet milling, and spray drying for drug substances and APIs.

We operate segregated areas for:

• Non-GMP production, focused on customized building blocks and RSMs,
• GMP-compliant manufacturing of advanced intermediates and active pharmaceutical ingredients.

Additionally, the facility includes dedicated production areas for both human and veterinary APIs, ensuring compliance and specialization across product categories.

The site offers > 1,000,000 L capacity.